e-Article
Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer.
Document Type
Academic Journal
Author
Drescher R; Clinic of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.; Köhler A; Clinic of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.; Seifert P; Clinic of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.; Aschenbach R; Institute of Diagnostic and Interventional Radiology, Jena University Hospital, 07747 Jena, Germany.; Ernst T; Department of Hematology and Oncology, Jena University Hospital, 07747 Jena, Germany.; Rauchfuß F; Department of General, Visceral and Vascular Surgery, Jena University Hospital, 07747 Jena, Germany.; Freesmeyer M; Clinic of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2227-9059
Abstract
Holmium-166 microspheres are used for the transarterial radioembolization (TARE) treatment of primary and secondary liver cancers. In this study, its efficacy regarding local tumor control and integration into the oncological treatment sequence of the first 20 patients treated in our institution were examined. A total of twenty-nine 166 Ho-TARE procedures were performed to treat hepatocellular carcinoma (HCC, fourteen patients), metastatic colorectal cancer (mCRC, four patients), intrahepatic cholangiocarcinoma (ICC, one patient), and hemangioendothelioma of the liver (HE, one patient). In eight patients, 166 Ho-TARE was the initial oncologic treatment. In patients with HCC, the median treated-liver progression-free survival (PFS), overall PFS, and overall survival after 166 Ho-TARE were 10.3, 7.3, and 22.1 months; in patients with mCRC, these were 2.6, 2.9, and 20.6 months, respectively. Survival after 166 Ho-TARE in the patients with ICC and HE were 5.2 and 0.8 months, respectively. Two patients with HCC were bridged to liver transplantation, and one patient with mCRC was downstaged to curative surgery. In patients with HCC, a median treatment-free interval of 7.3 months was achieved. In line with previous publications, 166 Ho-TARE was a feasible treatment option in patients with liver tumors, with favorable clinical outcomes in the majority of cases. It was able to achieve treatment-free intervals, served as bridging-to-transplant, and did not prevent subsequent therapies.